查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1931250

末期慢性腎臟病治療市場依治療類型、疾病階段、最終用戶、通路、作用機制及製劑分類，全球預測，2026-2032年

Late Stage Chronic Kidney Disease Therapeutics Market by Treatment Type, Disease Stage, End-User, Distribution Channel, Mechanism Of Action, Formulation - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，末期慢性腎臟病治療市場規模將達到 130.2 億美元，到 2026 年將成長至 141.6 億美元，複合年成長率為 9.88%，到 2032 年將達到 252 億美元。

關鍵市場統計數據
基準年 2025 130.2億美元
預計年份：2026年 141.6億美元
預測年份 2032 252億美元
複合年成長率 (%) 9.88%

這是一本簡潔而權威的入門讀物，全面闡述了塑造現代慢性腎臟病治療的臨床複雜性、治療創新和商業性需求。

末期慢性腎臟病（CKD）是患者照護的關鍵階段，臨床複雜性、醫療成本和治療創新在此交會整合。晚期患者需要多方面的干涉，包括腎臟替代治療、最佳化藥物治療以控制併發症和合併症，以及腎臟移植評估。臨床決策越來越注重在有限的醫療資源下，盡可能保留殘餘腎功能、降低心血管風險並提高病患的生活品質。

臨床、監管和商業性動態的重大變革正在重塑終末期慢性腎臟病的治療方法和優先事項。

末期慢性腎臟病領域正經歷多項變革，這些變革正在重新定義治療方法的研發、實施和評估方式。更精細的患者分層和生物標記的應用，使得更有針對性的干涉策略成為可能，從而延緩疾病進展並減少透析的啟動。同時，從先進的促紅血球生成療法到更具選擇性的磷酸鹽粘合劑和礦物質代謝調節劑，藥物治療的進步正在重新調整治療目標，以減少住院和心血管事件的發生。

對 2025 年美國關稅如何改變慢性腎臟病藥物供應鏈的韌性、籌資策略和商業性經濟進行了全面分析。

這些關稅於2025年生效，對末期慢性腎臟病相關治療藥物的全球供應鏈造成了即時且連鎖的壓力。從受影響地區購買原料藥、特殊輔料或成品製劑的製造商面臨著到岸成本增加的困境，迫使財務和採購團隊重新評估其籌資策略和庫存緩衝。為因應這項挑戰，各公司正加速近岸外包，實現供應商多元化，並增加對供應鏈可視性工具的投資，以降低風險敞口，確保注射劑和透析相關耗材等關鍵產品的持續供應。

深度細分分析揭示了治療類型、疾病階段、臨床環境、通路、支付方、作用機制和劑型如何共同決定策略和價值實現。

精細化的細分框架揭示了不同治療類別、疾病階段、醫療機構、分銷管道、支付方類型、作用機制和製劑形式所帶來的獨特需求促進因素和商業性槓桿。治療方法差異化定義了透析、藥物治療和移植路徑，其中藥物治療進一步細分為抗高血壓藥物、促紅血球生成素、磷酸鹽粘合劑和維生素D類似物。這種細分突顯了治療目標和預期結果如何影響臨床應用和商業化策略。將疾病階段分為3期、4期和5期，為介入時機提供了臨床藍圖。 3期和4期代表延緩疾病進展的機會，而5期則需要為腎臟替代治療和複雜的護理協調做好準備。

區域分析概述了美洲、歐洲、中東和非洲以及亞太市場在採用率、報銷和戰略進入考量方面的差異

區域趨勢決定了創新技術在哪些領域獲得應用，以及治療策略如何調整。在美洲，成熟的報銷機制和一體化的醫療保健系統往往有利於快速推廣療效顯著且成本效益高的臨床創新技術，而完善的透析網路和移植項目則造就了需求熱點地區。該地區的支付方談判和衛生技術評估流程促進了基於真實世界數據和結果導向合約的製定，從而確保創新技術的廣泛應用。

深入競爭考察差異化、夥伴關係、生產韌性和實證策略，協助企業在末期慢性腎臟病治療領域建立領導地位。

慢性腎臟病（CKD）後期治療藥物的競爭格局呈現出多元化的特點：既有擁有深厚臨床經驗的成熟廠商，也有專注於機制創新、致力於研發新型藥物的生物技術公司，還有著眼於醫療服務平台數位化的參與企業。現有廠商憑藉與透析服務提供者和醫院建立的穩固關係、強大的分銷網路以及豐富的上市後安全性數據，維持著市場地位。同時，新參與企業則優先考慮透過全新的作用機制、務實的試驗設計以及針對未被滿足的需求和潛在臨床影響最大的目標患者群體，實現顯著的差異化。

為產業領導者提供切實可行的策略建議，以協調證據產生、供應鏈韌性和支付方參與，從而加速技術採納和普及。

企業應優先產生高品質的真實世界證據，以證明治療性介入與降低住院率、延緩透析啟動以及改善病患報告結局之間的關聯。這些證據對於獲得有利的報銷條款和支持按績效付費合約至關重要。同時，企業也應設計以病人為中心的支援項目，以解決用藥依從性、多重疾病管理以及不同治療方法涉及從醫院過渡到家庭護理的治療方案。

透明的調查方法，詳細說明了數據三角驗證、同行檢驗和情境分析等措施，以確保得出可靠且可操作的結論。

本分析整合了同行評審的臨床文獻、監管指南、公共聲明以及與臨床專家、支付方和採購負責人進行的經驗證的檢驗，以確保對終末期慢性腎病藥物的全面了解。調查方法將臨床試驗結果與真實世界的用藥模式和供應鏈資訊進行三角驗證，從而得出對商業化和政策制定具有實際意義的結論。來自第一線臨床醫生和護理管理人員的定性意見被用於闡明藥物推廣障礙和治療路徑限制，而供應商和經銷商的觀點則用於評估營運風險。

為將治療創新轉化為末期慢性腎臟病患者療效的改善，需要對策略要務和相關人員的責任進行關鍵性綜合分析。

末期慢性腎病藥物正處於一個轉折點，這個轉折點受到科學進步、不斷演變的護理模式和政策調整的影響。僅靠臨床創新並不能保證產生影響。成功取決於差異化的治療方法、穩健的供應鏈、以實證醫學為基礎的支付方合作，以及整合符合透析中心、醫院和居家照護實際運作的交付模式。關稅和地緣政治動盪帶來的成本壓力凸顯了採取積極主動的籌資策略和合作合約解決方案的必要性，以確保患者能夠獲得維持生命的治療。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 末期慢性腎臟病治療市場（依治療方法）

  • 透析
  • 藥物治療
    • 抗高血壓藥物
    • 紅血球生成刺激因子
    • 磷酸鹽粘合劑
    • 維生素D類似物
  • 移植

第9章 依疾病階段分類的末期慢性腎臟病治療市場

  • 第三階段
  • 第四階段
  • 第五階段

第10章 末期慢性腎臟病藥物市場（依最終用戶分類）

  • 門診手術中心
  • 透析中心
  • 居家醫療環境
  • 醫院

第11章 末期慢性腎臟病藥物市場（依通路分類）

  • 離線
  • 線上

第12章 末期慢性腎臟病藥物市場依作用機轉分類

  • 紅血球生成刺激
  • 磷酸鹽結合
  • RAAS抑制
  • 維生素D受體激活

第13章 依劑型分類的末期慢性腎臟病治療市場

  • 注射
  • 口服

第14章 各地區末期慢性腎臟病藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 末期慢性腎臟病藥物市場（依組別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國末期慢性腎臟病藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國末期慢性腎臟病藥物市場

第18章：中國末期慢性腎臟病治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Akebia Therapeutics, Inc.
  • Amgen Inc.
  • Ardelyx, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Chinook Therapeutics, Inc.
  • Eli Lilly and Company
  • FibroGen, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • KBP Biosciences Co., Ltd.
  • Maze Therapeutics, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • ProKidney, Inc.
  • Travere Therapeutics, Inc.
Product Code: MRR-7B550E008DE6

The Late Stage Chronic Kidney Disease Therapeutics Market was valued at USD 13.02 billion in 2025 and is projected to grow to USD 14.16 billion in 2026, with a CAGR of 9.88%, reaching USD 25.20 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.02 billion
Estimated Year [2026] USD 14.16 billion
Forecast Year [2032] USD 25.20 billion
CAGR (%) 9.88%

A concise authoritative introduction framing clinical complexity, therapeutic innovation, and commercial imperatives shaping late-stage chronic kidney disease care today

Late-stage chronic kidney disease (CKD) represents a pivotal junction in patient care where clinical complexity, care delivery costs, and therapeutic innovation converge. Patients progressing to advanced stages require multifaceted interventions that span renal replacement therapies, optimized pharmacotherapy to manage comorbidities and complications, and transplant evaluation. Clinical decision-making increasingly emphasizes preserving residual renal function, mitigating cardiovascular risk, and improving quality of life while navigating constrained health-system resources.

Over recent years, breakthroughs in pharmacologic mechanisms and care models have reshaped treatment algorithms and stakeholder expectations. At the same time, payers and providers are adapting to new cost structures and outcome-based contracting models that influence access to novel agents and supportive technologies. For industry leaders, understanding the interplay between clinical efficacy, safety profiles, delivery settings, and reimbursement pathways is essential to design credible value propositions and to prioritize investments that will deliver measurable patient and system benefits.

This executive summary synthesizes the most consequential shifts in late-stage CKD therapeutics, evaluates how U.S. tariff measures in 2025 are altering supply chain and commercial dynamics, and highlights segmentation, regional, and competitive insights to guide strategic planning. The focus is on translating evidence and policy trends into actionable guidance for clinicians, commercial teams, and policy makers charged with improving outcomes for patients with advanced CKD.

Critical transformative shifts in clinical, regulatory, and commercial dynamics that are reshaping late-stage chronic kidney disease treatment approaches and priorities

The late-stage CKD arena is experiencing several transformative shifts that are redefining how therapies are developed, delivered, and evaluated. Precision in patient stratification and the adoption of biomarkers are enabling more targeted intervention strategies that can delay progression and reduce dialysis initiation. Concurrently, advances in pharmacotherapies-ranging from refined erythropoiesis-stimulating approaches to more selective phosphate binders and modulators of mineral metabolism-are recalibrating treatment objectives toward reducing hospitalizations and cardiovascular events.

Care delivery is also evolving: there is a growing emphasis on home-based modalities and integrated care pathways that connect ambulatory surgical centers, dialysis facilities, and hospital networks with remote monitoring platforms to support patient adherence and early intervention. Payment models are shifting toward value-based arrangements that reward outcomes rather than volume, prompting manufacturers to demonstrate real-world effectiveness and to design risk-sharing agreements that align incentives with health systems and payers.

Finally, regulatory expectations and accelerated review pathways for therapies addressing unmet needs are encouraging sponsors to pursue novel endpoints and adaptive trial designs. As a result, companies that can demonstrate robust clinical differentiation, manageable safety profiles, and credible economic value will be best positioned to lead in the evolving marketplace.

Comprehensive analysis of how United States tariff measures implemented in 2025 have altered supply chain resilience, sourcing strategies, and commercial economics for CKD therapeutics

Tariff actions enacted in 2025 have exerted immediate and cascading pressures on global supply chains for therapeutics relevant to late-stage chronic kidney disease. Manufacturers sourcing active pharmaceutical ingredients, specialty excipients, or finished formulations from impacted jurisdictions have experienced higher landed costs, prompting finance and procurement teams to reassess sourcing strategies and inventory buffers. In response, firms have accelerated nearshoring, diversified supplier bases, and increased investments in supply chain visibility tools to mitigate exposure and ensure continuity of critical products such as injectables and dialysis-related disposables.

Commercial teams must now account for the tariff-driven cost implications when designing pricing and contracting strategies. Negotiations with hospital systems and dialysis networks are increasingly centered on total cost of care considerations, with buyers demanding greater transparency around cost drivers and suppliers exploring bundled offerings that combine product with services to preserve access. Smaller manufacturers face heightened pressure as compressed margins and elevated compliance burdens make it more challenging to absorb tariff-related increases without transferring costs to providers or payers.

Regulatory and policy stakeholders are also responding. There is a renewed focus on strategic stockpiles for essential renal care products, expedited approvals for alternate suppliers, and discussions around tariff exemptions for life-sustaining medicines. For industry leaders, proactive scenario planning that models tariff impacts across sourcing, manufacturing, and go-to-market channels will be crucial to sustain supply reliability and to maintain competitive positioning in a tighter cost environment.

Deep segmentation insights revealing how treatment types, disease stages, care settings, channels, payers, mechanisms, and formulations jointly dictate strategy and value realization

A nuanced segmentation framework reveals distinct demand drivers and commercial levers across treatment categories, disease stages, care settings, distribution channels, payer types, mechanisms of action, and formulations. Treatment modality distinctions separate dialysis, pharmacotherapy, and transplantation pathways, with pharmacotherapy further differentiated by antihypertensives, erythropoiesis-stimulating agents, phosphate binders, and vitamin D analogs; this split underscores how therapeutic purpose and expected outcomes shape clinical adoption and commercialization strategies. Disease stage segmentation into Stage 3, Stage 4, and Stage 5 provides a clinical roadmap for timing intervention, with Stage 3 and Stage 4 representing windows for slowing progression and Stage 5 demanding readiness for renal replacement therapies and complex care coordination.

End-user segmentation, spanning ambulatory surgical centers, dedicated dialysis centers, home care settings, and acute-care hospitals, highlights the importance of designing delivery models and support services that match the operational realities and procurement practices of each setting. Distribution channels including hospital pharmacy, online pharmacy, and retail pharmacy create different patient access pathways and influence adherence, continuity of care, and margin structures. Payer segmentation among government insurance, out-of-pocket payers, and private insurance reveals the need for differentiated reimbursement strategies and value dossiers that address affordability, coverage criteria, and prior authorization hurdles.

Mechanism-of-action categories such as erythropoiesis stimulation, phosphate binding, renin-angiotensin-aldosterone system inhibition, and vitamin D receptor activation clarify therapeutic positioning and combination potential, guiding clinical development and real-world evidence generation. Formulation distinctions between injectable and oral products affect administration logistics, patient preference, and channel economics, requiring manufacturers to align patient support programs and distribution partnerships accordingly. Together, these segmentation dimensions form a holistic picture that can inform product prioritization, targeted clinical evidence generation, and adaptive commercial models tailored to each intersection of clinical need and care setting.

Regional intelligence summarizing how Americas, Europe Middle East & Africa, and Asia-Pacific markets diverge in adoption, reimbursement, and strategic entry considerations

Regional dynamics shape where innovation gains traction and how therapeutic strategies must be adapted. In the Americas, mature reimbursement frameworks and integrated care systems tend to favor rapid uptake of clinical innovations that demonstrate outcomes and cost offsets, while established dialysis networks and transplant programs create concentrated demand centers. Payor negotiations and health technology assessment processes in this region incentivize robust real-world evidence and outcomes-based contracting to secure placement.

Europe, Middle East & Africa present diverse regulatory and reimbursement landscapes that span highly centralized procurement models and fragmented markets with variable access. In many countries within this region, procurement is influenced by national formularies and tender processes, prompting manufacturers to tailor pricing strategies and local evidence packages. The heterogeneity of healthcare infrastructure-from advanced tertiary centers to constrained rural settings-requires flexible distribution and support models that can bridge capability gaps.

Asia-Pacific demonstrates a mixture of high-growth adoption corridors and markets where access is constrained by funding limitations. Rapid demographic change and rising CKD prevalence in several countries create expanding demand for both pharmacotherapies and renal replacement services, while governments increasingly prioritize domestic manufacturing resilience and supply chain security. Across all regions, strategic market entry planning that accounts for regulatory timelines, local clinical guidelines, and payer expectations will be essential to convert clinical innovation into sustained patient impact.

Actionable competitive insights on differentiation, partnerships, manufacturing resilience, and evidence strategies that define leadership in late-stage CKD therapeutics

The competitive landscape in late-stage CKD therapeutics is characterized by a mix of legacy manufacturers with deep clinical experience, specialty biotech firms introducing mechanism-driven innovation, and emerging entrants focused on care delivery platforms and digital enablement. Incumbent players leverage established relationships with dialysis providers and hospitals, strong distribution networks, and extensive post-market safety data to sustain market presence. In contrast, newer entrants prioritize clear differentiation through novel mechanisms of action, pragmatic trial designs, and targeted patient segments where unmet need and potential clinical impact are greatest.

Strategic partnerships are increasingly common, combining biopharmaceutical innovation with supply chain specialists, digital health vendors, and specialty pharmacies to deliver comprehensive solutions that address adherence, monitoring, and patient support. Licensing and co-development agreements can accelerate time-to-market for promising compounds while mitigating commercialization risk. Manufacturing scale and quality assurance are also decisive competitive factors, with companies investing in manufacturing redundancy and regulatory compliance to safeguard supply and to satisfy large institutional buyers.

Companies that best align clinical value with payer-relevant outcomes, and that demonstrate credible plans to manage distribution and tariff-related cost challenges, will have an advantage. Leadership in late-stage CKD will depend not only on therapeutic efficacy but also on the ability to execute integrated commercial models that combine product, services, and real-world evidence generation.

Practical strategic recommendations for industry leaders to align evidence generation, supply chain resilience, and payer engagement to accelerate adoption and access

Companies should prioritize generating high-quality real-world evidence that links therapeutic interventions to reductions in hospitalization, delay of dialysis initiation, and improvements in patient-reported outcomes. This evidence will be essential to secure favorable reimbursement terms and to support outcomes-based contracting. Concurrently, manufacturers must design patient-centric support programs that address adherence, multimorbidity management, and transitions between care settings, particularly for therapies that shift care from hospital to home.

From an operational perspective, diversifying supply chains and instituting flexible sourcing strategies will reduce vulnerability to geopolitical and tariff-related shocks. Investment in manufacturing redundancy and nearshoring options should be weighed against long-term cost implications and the need for regulatory harmonization. Commercial teams must craft differentiated value propositions for key end-users-ambulatory surgical centers, dialysis centers, home care providers, and hospitals-while aligning distribution strategies across hospital, online, and retail pharmacy channels to maximize access and continuity of care.

Finally, engaging proactively with payers and policy makers can accelerate access pathways. Collaboration on pilot programs, shared-savings models, and corridor studies that demonstrate system-level benefits will open pathways to broader adoption. Leaders that integrate clinical excellence, supply chain resilience, and payer-aligned evidence programs will be positioned to convert innovation into sustained patient and commercial value.

Transparent research methodology detailing data triangulation, expert validation, and scenario analysis employed to ensure robust and actionable conclusions

This analysis synthesizes peer-reviewed clinical literature, regulatory guidance, public policy statements, and verified primary interviews with clinical specialists, payers, and procurement professionals to ensure a comprehensive understanding of late-stage CKD therapeutics. The methodological approach triangulates clinical trial outcomes with real-world utilization patterns and supply chain intelligence to derive actionable implications for commercialization and policy. Qualitative inputs from frontline clinicians and care managers were used to contextualize adoption barriers and care pathway constraints, while supplier and distributor perspectives informed assessments of operational risk.

Analytical rigor was maintained through cross-validation of thematic findings against multiple independent sources and through scenario analyses that explored supply chain, tariff, and reimbursement contingencies. Where appropriate, sensitivity checks were applied to ensure conclusions remained robust across plausible variations in policy and clinical practice. Stakeholder feedback loops, including expert review rounds, were executed to refine interpretations and to surface practical recommendations. This layered methodology balances empirical evidence with practitioner insight to deliver conclusions tailored for decision-makers in industry and healthcare delivery.

Conclusive synthesis of strategic imperatives and stakeholder responsibilities to translate therapeutic innovation into improved outcomes for late-stage CKD patients

Late-stage CKD therapeutics are at an inflection point shaped by scientific advances, evolving care models, and shifting policy levers. Clinical innovation alone will not guarantee impact; success will hinge on integrating therapeutic differentiation with resilient supply chains, payer-aligned evidence generation, and delivery models that meet the operational realities of dialysis centers, hospitals, and home-based care. Tariff-induced cost pressures and geopolitical volatility underscore the need for proactive sourcing strategies and collaborative contracting solutions to preserve access to life-sustaining therapies.

For manufacturers, the imperative is clear: invest in real-world evidence generation, design flexible commercial models that address diverse end-user needs, and prioritize manufacturing and distribution strategies that mitigate systemic risk. For clinicians and health systems, there is an opportunity to leverage new therapeutics in conjunction with care pathway redesigns that reduce progression and improve patient-centered outcomes. Policy makers can further enable progress by aligning reimbursement incentives with value and by considering targeted measures to protect supplies of essential renal medicines. Together, these coordinated actions can transform late-stage CKD management toward better outcomes and more sustainable care delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Late Stage Chronic Kidney Disease Therapeutics Market, by Treatment Type

  • 8.1. Dialysis
  • 8.2. Pharmacotherapy
    • 8.2.1. Antihypertensives
    • 8.2.2. Erythropoiesis-Stimulating Agents
    • 8.2.3. Phosphate Binders
    • 8.2.4. Vitamin D Analogs
  • 8.3. Transplantation

9. Late Stage Chronic Kidney Disease Therapeutics Market, by Disease Stage

  • 9.1. Stage 3
  • 9.2. Stage 4
  • 9.3. Stage 5

10. Late Stage Chronic Kidney Disease Therapeutics Market, by End-User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Dialysis Centers
  • 10.3. Home Care Settings
  • 10.4. Hospitals

11. Late Stage Chronic Kidney Disease Therapeutics Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Late Stage Chronic Kidney Disease Therapeutics Market, by Mechanism Of Action

  • 12.1. Erythropoiesis Stimulation
  • 12.2. Phosphate Binding
  • 12.3. RAAS Inhibition
  • 12.4. Vitamin D Receptor Activation

13. Late Stage Chronic Kidney Disease Therapeutics Market, by Formulation

  • 13.1. Injectable
  • 13.2. Oral

14. Late Stage Chronic Kidney Disease Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Late Stage Chronic Kidney Disease Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Late Stage Chronic Kidney Disease Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Late Stage Chronic Kidney Disease Therapeutics Market

18. China Late Stage Chronic Kidney Disease Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Akebia Therapeutics, Inc.
  • 19.7. Amgen Inc.
  • 19.8. Ardelyx, Inc.
  • 19.9. Astellas Pharma Inc.
  • 19.10. AstraZeneca PLC
  • 19.11. Bayer AG
  • 19.12. Boehringer Ingelheim International GmbH
  • 19.13. Chinook Therapeutics, Inc.
  • 19.14. Eli Lilly and Company
  • 19.15. FibroGen, Inc.
  • 19.16. Gilead Sciences, Inc.
  • 19.17. GlaxoSmithKline PLC
  • 19.18. KBP Biosciences Co., Ltd.
  • 19.19. Maze Therapeutics, Inc.
  • 19.20. Novartis AG
  • 19.21. Novo Nordisk A/S
  • 19.22. Pfizer Inc.
  • 19.23. ProKidney, Inc.
  • 19.24. Travere Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS-STIMULATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS-STIMULATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS-STIMULATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 3, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 3, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 3, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 4, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 4, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 4, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 5, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 5, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 5, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY RAAS INHIBITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY RAAS INHIBITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY RAAS INHIBITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D RECEPTOR ACTIVATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D RECEPTOR ACTIVATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D RECEPTOR ACTIVATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 149. GCC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. GCC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 154. GCC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. GCC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 173. G7 LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. G7 LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 177. G7 LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. G7 LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. G7 LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 180. G7 LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 181. NATO LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. NATO LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 185. NATO LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 186. NATO LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. NATO LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 188. NATO LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)